Gunderson Dettmer Client JenaValve Enters Agreement to be Acquired by Edwards Lifesciences

Gunderson Dettmer represented client JenaValve Technology, a pioneer in the transcatheter treatment of aortic regurgitation (AR), in its agreement to be acquired by Edwards Lifesciences, a global leader of patient-focused innovations for structural heart disease and critical care monitoring.

JenaValve presented positive results of its U.S. pivotal trial for the treatment of symptomatic, severe AR in high-risk patients late last year. Edwards anticipates FDA approval of the JenaValve Trilogy Heart Valve System in late 2025, which will represent the first approved therapy for patients suffering from AR.

In the announcement of the acquisition, Edwards Lifesciences CEO Bernard Zovighian said, “[This acquisition] expand[s] our opportunities to address the unmet needs of aortic regurgitation…patients around the world. We are pleased to enter these structural heart therapeutic areas with innovation, world-class science and clinical evidence to provide access to life-saving technologies for patients around the world.”

The Gunderson Dettmer team was led by corporate partner Jeff Thacker and M&A partner John Olson, with key assistance from M&A partner Jenn Sayles Okorn and corporate Associate Jordan Murray, the team also included corporate associates Riley Millender, Benjamin Cohen-Kurzrock and Seth Bertolucci, M&A associate Monica Dion, strategic transactions and licensing partner Ryan Enchelmayer and associates Alex Lee and Anthony Farnesi, executive compensation partner Heather Aune and associates Erik Ward and Elisabeth Bernabe, tax partner Lily Kim, data privacy partner Anna Westfelt and associate James Gately, employment & labor Of Counsel Jeff Salomon and associate Mark Macchi and tax/fund associate Sasha Benincasa.

Companies
JenaValve Technology
Edwards Lifesciences